VANCOUVER, British Columbia , Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42 nd Annual J.P.
Continue Reading
Net l oss for the first nine months of 20 23 decreased by 44% as compared to the same period in 2022 Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Updated clinical results from Phase 1b/2 study
Continue Reading
VANCOUVER, British Columbia , Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies London
Continue Reading
VANCOUVER, British Columbia , Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close
Continue Reading
VANCOUVER, British Columbia , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors
Continue Reading
Net loss for the first six months of 2023 decrease d by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Presented full clinical results from Phase 2b study of
Continue Reading
VANCOUVER, British Columbia , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2023 18 th
Continue Reading
VANCOUVER, British Columbia , July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August
Continue Reading
VANCOUVER, British Columbia , July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conference: BTIG Virtual
Continue Reading
VANCOUVER, British Columbia , June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023 .
Continue Reading